Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

Inclusion Criteria:

- Pathologically proven acute myeloid leukemia (AML) or intermediate, high-risk, or very
high risk Myelodysplastic Syndrome (MDS) as defined by the World Health Organization
(WHO) criteria or Revised International Prognostic Scoring System (IPSS-R) which is
relapsed or refractory (R/R) to standard therapy and/or for which standard therapy is
contraindicated or which has not adequately responded to standard therapy.

- Patients must have documented IDH1-R132 gene-mutated disease as evaluated by the site

- Good performance status

- Good kidney and liver function

Exclusion Criteria:

- Patients with symptomatic central nervous system (CNS) metastases or other tumor
location (such as spinal cord compression, other compressive mass, uncontrolled
painful lesion, bone fracture, etc.) necessitating an urgent therapeutic intervention,
palliative care, surgery or radiation therapy

- Congestive heart failure (New York Heart Association Class III or IV) or unstable
angina pectoris. Previous history of myocardial infarction within 1 year prior to
study entry, uncontrolled hypertension or uncontrolled arrhythmias

- Pulmonary disease (e.g. COPD, asthma, etc) that is not controlled (moderate to severe
symptoms) with current medication

- Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic
therapy